Bradley, R, Braybrooke, J, Gray, R, Hills, R K, Liu, Z, Pan, H, Peto, R, Dodwell, D, McGale, P, Taylor, C, Francis, P A, Gnant, M, Perrone, F, Regan, M M, Berry, R, Boddington, C, Clarke, M, Davies, C, Davies, L, Duane, F, Evans, V, Gay, J, Gettins, L, Godwin, J, James, S, Liu, H, MacKinnon, E, Mannu, G, McHugh, T, Morris, P, Read, S, Straiton, E, Jakesz, R, Fesl, C, Pagani, O, Gelber, R, De Laurentiis, M, De Placido, S, Gallo, C, Albain, K, Anderson, S, Arriagada, R, Bartlett, J, Bergsten-Nordström, E, Bliss, J, Brain, E, Carey, L, Coleman, R, Cuzick, J, Ejlertsen, B & Early Breast Cancer Trialists' Collaborative Group (EBCTCG) 2022, ' Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression : a patient-level meta-analysis of 7030 women from four randomised trials ', The Lancet Oncology, vol. 23, no. 3, pp. 382-392 . https://doi.org/10.1016/S1470-2045(21)00758-0 Bradley, R, Braybrooke, J, Gray, R, Hills, R K, Liu, Z, Pan, H, Peto, R, Dodwell, D, Mcgale, P, Taylor, C, Francis, P A, Gnant, M, Perrone, F, Regan, M M, Berry, R, Boddington, C, Clarke, M, Davies, C, Davies, L, Duane, F, Evans, V, Gay, J, Gettins, L, Godwin, J, James, S, Liu, H, Mackinnon, E, Mannu, G, Mchugh, T, Morris, P, Read, S, Straiton, E, Jakesz, R, Fesl, C, Pagani, O, Gelber, R, De Laurentiis, M, De Placido, S, Gallo, C, Albain, K, Anderson, S, Arriagada, R, Bartlett, J, Bergsten-nordström, E, Bliss, J, Brain, E, Carey, L, Coleman, R, Cuzick, J, Davidson, N, Del Mastro, L, Di Leo, A, Dignam, J, Dowsett, M, Ejlertsen, B, Goetz, M, Goodwin, P, Halpin-murphy, P, Hayes, D, Hill, C, Jagsi, R, Janni, W, Loibl, S, Mamounas, E P, Martín, M, Mukai, H, Nekljudova, V, Norton, L, Ohashi, Y, Pierce, L, Poortmans, P, Pritchard, K I, Raina, V, Rea, D, Robertson, J, Rutgers, E, Spanic, T, Sparano, J, Steger, G, Tang, G, Toi, M, Tutt, A, Viale, G, Wang, X, Whelan, T, Wilcken, N, Wolmark, N, Cameron, D, Bergh, J & Swain, S M 2022, ' Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials ', The Lancet Oncology, vol. 23, no. 3, pp. 382-392 . https://doi.org/10.1016/S1470-2045(21)00758-0
NPJ breast cancer, Vol. 7, no.1, p. 150 [1-17] (2021) NPJ BREAST CANCER npj Breast Cancer npj Breast Cancer, Nature, 2021, 7 (1), ⟨10.1038/s41523-021-00346-1⟩ NPJ Breast Cancer El Bairi, K, Haynes, H R, Blackley, E, Fineberg, S, Shear, J, Turner, S, de Freitas, J R, Sur, D, Amendola, L C, Gharib, M, Kallala, A, Arun, I, Azmoudeh-Ardalan, F, Fujimoto, L, Sua, L F, Liu, S W, Lien, H C, Kirtani, P, Balancin, M, El Attar, H, Guleria, P, Yang, W, Shash, E, Chen, I C, Bautista, V, Do Prado Moura, J F, Rapoport, B L, Castaneda, C, Spengler, E, Acosta-Haab, G, Frahm, I, Sanchez, J, Castillo, M, Bouchmaa, N, Md Zin, R R, Shui, R, Onyuma, T, Yang, W, Husain, Z, Willard-Gallo, K, Coosemans, A, Perez, E A, Provenzano, E, Choi, H J, Laenkholm, A V, Stovgaard, E I S, Nielsen, T, Balslev, E, Sharma, A, Singh, R & The International Immuno-Oncology Biomarker Working Group 2021, ' The tale of TILs in breast cancer : A report from The International Immuno-Oncology Biomarker Working Group ', npj Breast Cancer, vol. 7, no. 1, 150 . https://doi.org/10.1038/s41523-021-00346-1 npj Breast Cancer, Vol 7, Iss 1, Pp 1-17 (2021)